Claritev (NYSE:CTEV) CEO Travis Dalton Buys 15,380 Shares

Claritev (NYSE:CTEV) CEO Travis Dalton purchased 15,380 shares of the stock in a transaction dated Friday, February 27th. The shares were acquired at an average cost of $13.00 per share, for a total transaction of $199,940.00. Following the completion of the acquisition, the chief executive officer owned 24,952 shares of the company’s stock, valued at approximately $324,376. This represents a 160.68% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Claritev Price Performance

Shares of Claritev stock traded up $0.95 during trading on Monday, hitting $14.42. 362,312 shares of the company’s stock traded hands, compared to its average volume of 230,734. Claritev has a 1 year low of $12.04 and a 1 year high of $74.07. The business has a 50-day simple moving average of $28.94 and a 200-day simple moving average of $46.69. The stock has a market capitalization of $238.07 million, a P/E ratio of -0.83 and a beta of 0.61.

Wall Street Analysts Forecast Growth

CTEV has been the subject of a number of research reports. Citigroup reduced their target price on shares of Claritev from $63.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. UBS Group reiterated a “buy” rating on shares of Claritev in a research note on Tuesday, February 24th. Wells Fargo & Company set a $30.00 price objective on Claritev and gave the stock an “equal weight” rating in a research note on Tuesday, February 24th. Guggenheim reaffirmed a “buy” rating on shares of Claritev in a report on Tuesday, February 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Claritev in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $29.67.

Institutional Trading of Claritev

Several institutional investors and hedge funds have recently added to or reduced their stakes in CTEV. State of Wyoming bought a new position in Claritev in the 4th quarter worth approximately $25,000. Ameritas Investment Partners Inc. purchased a new position in shares of Claritev in the third quarter worth $42,000. Legal & General Group Plc purchased a new position in shares of Claritev in the third quarter worth $45,000. Los Angeles Capital Management LLC bought a new position in shares of Claritev during the fourth quarter worth $45,000. Finally, BNP Paribas Financial Markets purchased a new position in Claritev during the third quarter valued at $79,000. Institutional investors own 87.15% of the company’s stock.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.